Skip to content

The Invia Motion at Cesarean Study

Medela INVIA Motion NPWT System for Prophylactic Use on Surgical Incision After Cesarean Delivery

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04365452
Enrollment
20
Registered
2020-04-28
Start date
2020-03-10
Completion date
2020-12-31
Last updated
2023-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section; Infection, Negative Pressure Wound Therapy

Brief summary

To assess patient centered outcomes of the Medela INVIA Motion prophylactic NPWT system at cesarean delivery.

Detailed description

This study will be a two center case series of women undergoing caesarean delivery conducted at two medical centers in Indianapolis, Indiana. All patients meeting inclusion criteria will be included. All enrolled patients will receive the Medela INVIA Motion prophylactic NPWT device. Visit A: Interventional Procedure All enrolled patients will receive the Medela INVIA Motion device placed by the patient's surgeon after the skin is closed with subcuticular suture or staples. Research staff and clinicians (labor & delivery and postpartum nurses, OR technicians, physicians, etc.) involved in the study will receive formal training on how to place and remove the prophylactic NPWT device. Visit B: Post Procedure until Discharge Patients will be monitored daily while in the hospital by clinical staff and/or research staff for complications. The negative pressure wound therapy dressing will be removed on the day of discharge. If the patient remains hospitalized for more than 7 days, the dressing will be removed on postoperative day 7. Replacement of any dressing that is saturated. If a patient develops infection with the NPWT device in place the device will be removed and the patient given standard SSI therapy as outlined below. Patients will be educated about the signs and symptoms of infection and other study outcomes and encouraged to call their provider if these should arise. Research staff document inpatient course regarding SSI. Management of surgical site infections will follow the Practice Guidelines of the Infectious Diseases Society of America. Visit C: Postpartum Follow Up We will use active surveillance by research staff to ascertain surgical site infections: Research staff will follow-up with the research participant at time of discharge or within 48 hours post discharge (postpartum day 1-9) to assess for adverse events, assess the participant's pain, obtain their satisfaction with their dressing and aesthetic appearance of the incision. Research staff will call subjects on approximately postoperative day 30 (±2 days). They will ask the patient standardized questions regarding wound complications, patient satisfaction, pain and aesthetic appearance. If the patient reports a hospital, clinic, or ER visit not associated with the study centers, the staff will obtain the name of the medical facility and request the records. The EQ-5D-3L quality of life questionnaire will be administered at the 30-day call. Medical records from postpartum clinic visits as well as records of unscheduled visits (to any hospital clinic or ER) will be sought to ascertain study outcomes. At the time of the subject's standard of care postpartum appointment about 4-6 weeks after inpatient hospital discharge research staff will collect information on outcomes, pain and patient satisfaction. If the patient does not attend the clinical postpartum visit, the study staff will contact the subject by phone to collect the data.

Interventions

DEVICEInvia Motion

Invia Motion NPWT system at cesarean delivery

Sponsors

Medela AG
CollaboratorINDUSTRY
Indiana University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Medela Invia pump

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

1. Scheduled/non-labor or unscheduled/labor cesarean delivery 2. Gestational age greater than or equal to 23 weeks

Exclusion criteria

1. Unwilling or unable to provide consent 2. Non-availability for postoperative follow-up 3. Contraindication to NPWT

Design outcomes

Primary

MeasureTime frameDescription
Pain Scores: Discharge Time FrameAt post-operative day 3 (+/- 1 days)Pain scores (pain score on scale of 0 - 10); 0 represents no pain, 10 represents highest pain
Pain Scores: Scores Postpartum Day 30At postoperative day 30 (+/- 2 days)Pain scores (pain score on scale of 0 - 10); 0 represents no pain, 10 represents highest pain
Patient Satisfaction: Scores Discharge Time FrameAt postoperative day 3 (+/- 1 days)Patient satisfaction scores (satisfaction score on scale of 0 - 10); 0 represents no satisfaction, 10 represents highest satisfaction
Patient Satisfaction: Scores Postpartum Day 30At postoperative day 30 (+/- 2 days)Patient satisfaction scores (satisfaction score on scale of 0 - 10); 0 represents no satisfaction, 10 represents highest satisfaction
Patient Satisfaction With Aesthetic Appearance: ScaleAt postoperative day 30 (+/- 2 days)Patient satisfaction with aesthetic appearance (satisfaction score on scale of 0 - 10); 0 represents no satisfaction, 10 represents highest satisfaction

Secondary

MeasureTime frameDescription
Allergic Reaction; Safety Outcomes4-6 Weeks PostpartumSafety outcome; proportion of allergic reaction to wound dressing
Wound Infection; Proportion of Incidence4-6 Weeks PostpartumComposite wound complication; wound infection as diagnosed by treating clinician
Wound Bleeding; Safety Outcomes4-6 Weeks PostpartumSafety outcome; proportion of wound bleeding
Wound Separation; Proportion of Incidence4-6 Weeks PostpartumComposite wound complication; wound separation as diagnosed by treating clinician
Seroma; Proportion of Incidence4-6 Weeks PostpartumComposite wound complication; seroma as diagnosed by treating clinician
Antibiotics Prescribed for Presumed SSI; Proportion of Incidence4-6 Weeks PostpartumComposite wound complication; antibiotics prescribed by treating clinician for wound-related infection
Skin Blistering; Safety Outcomes4-6 Weeks PostpartumSafety outcome; proportion of incidence of skin blistering around surgical wound

Countries

United States

Participant flow

Pre-assignment details

All patient undergoing cesarean delivery who consented were included

Participants by arm

ArmCount
Invia Motion Arm
Invia Motion: Invia Motion NPWT system at cesarean delivery
20
Total20

Baseline characteristics

CharacteristicInvia Motion Arm
Age, Continuous25 years
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
19 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
6 Participants
Race (NIH/OMB)
More than one race
0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
14 Participants
Sex: Female, Male
Female
20 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
0 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Pain Scores: Discharge Time Frame

Pain scores (pain score on scale of 0 - 10); 0 represents no pain, 10 represents highest pain

Time frame: At post-operative day 3 (+/- 1 days)

ArmMeasureValue (MEDIAN)
Invia Motion ArmPain Scores: Discharge Time Frame2.5 score on a scale
Primary

Pain Scores: Scores Postpartum Day 30

Pain scores (pain score on scale of 0 - 10); 0 represents no pain, 10 represents highest pain

Time frame: At postoperative day 30 (+/- 2 days)

ArmMeasureValue (MEDIAN)
Invia Motion ArmPain Scores: Scores Postpartum Day 300 score on a scale
Primary

Patient Satisfaction: Scores Discharge Time Frame

Patient satisfaction scores (satisfaction score on scale of 0 - 10); 0 represents no satisfaction, 10 represents highest satisfaction

Time frame: At postoperative day 3 (+/- 1 days)

ArmMeasureValue (MEDIAN)
Invia Motion ArmPatient Satisfaction: Scores Discharge Time Frame10 score on a scale
Primary

Patient Satisfaction: Scores Postpartum Day 30

Patient satisfaction scores (satisfaction score on scale of 0 - 10); 0 represents no satisfaction, 10 represents highest satisfaction

Time frame: At postoperative day 30 (+/- 2 days)

ArmMeasureValue (MEDIAN)
Invia Motion ArmPatient Satisfaction: Scores Postpartum Day 3010 score on a scale
Primary

Patient Satisfaction With Aesthetic Appearance: Scale

Patient satisfaction with aesthetic appearance (satisfaction score on scale of 0 - 10); 0 represents no satisfaction, 10 represents highest satisfaction

Time frame: At postoperative day 30 (+/- 2 days)

ArmMeasureValue (MEDIAN)
Invia Motion ArmPatient Satisfaction With Aesthetic Appearance: Scale10 score on a scale
Secondary

Allergic Reaction; Safety Outcomes

Safety outcome; proportion of allergic reaction to wound dressing

Time frame: 4-6 Weeks Postpartum

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Invia Motion ArmAllergic Reaction; Safety Outcomes0 Participants
Secondary

Antibiotics Prescribed for Presumed SSI; Proportion of Incidence

Composite wound complication; antibiotics prescribed by treating clinician for wound-related infection

Time frame: 4-6 Weeks Postpartum

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Invia Motion ArmAntibiotics Prescribed for Presumed SSI; Proportion of Incidence0 Participants
Secondary

Seroma; Proportion of Incidence

Composite wound complication; seroma as diagnosed by treating clinician

Time frame: 4-6 Weeks Postpartum

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Invia Motion ArmSeroma; Proportion of Incidence0 Participants
Secondary

Skin Blistering; Safety Outcomes

Safety outcome; proportion of incidence of skin blistering around surgical wound

Time frame: 4-6 Weeks Postpartum

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Invia Motion ArmSkin Blistering; Safety Outcomes0 Participants
Secondary

Wound Bleeding; Safety Outcomes

Safety outcome; proportion of wound bleeding

Time frame: 4-6 Weeks Postpartum

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Invia Motion ArmWound Bleeding; Safety Outcomes0 Participants
Secondary

Wound Infection; Proportion of Incidence

Composite wound complication; wound infection as diagnosed by treating clinician

Time frame: 4-6 Weeks Postpartum

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Invia Motion ArmWound Infection; Proportion of Incidence0 Participants
Secondary

Wound Separation; Proportion of Incidence

Composite wound complication; wound separation as diagnosed by treating clinician

Time frame: 4-6 Weeks Postpartum

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Invia Motion ArmWound Separation; Proportion of Incidence0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026